[{"id":"2dc1fa48-405c-43a2-8874-34fe5b578aec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04824794","created_at":"2022-12-14T16:58:25.975Z","updated_at":"2024-07-02T16:34:59.269Z","phase":"Phase 1/2","brief_title":"GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT04824794","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"}]